Ourania Preventza1, Ahmed S Mohamed2, Denton A Cooley2, Victor Rodriguez3, Faisal G Bakaeen4, Lorraine D Cornwell5, Shuab Omer5, Joseph S Coselli3. 1. Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex; Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex. Electronic address: opsmile01@aol.com. 2. Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex. 3. Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex; Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex. 4. Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex; Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Division of Cardiothoracic Surgery, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Tex. 5. Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Division of Cardiothoracic Surgery, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Tex.
Abstract
OBJECTIVES: We examined the early and midterm outcomes of homograft use in reoperative aortic root and proximal aortic surgery for endocarditis and estimated the associated risk of postoperative reinfection. METHODS: From January 2001 to January 2014, 355 consecutive patients underwent reoperation of the proximal thoracic aorta. Thirty-nine patients (10.9%; mean age, 55.4 ± 13.3 years) presented with active endocarditis; 30 (76.9%) had prosthetic aortic root infection with or without concomitant ascending and arch graft infection, and 9 (23.1%) had proximal ascending aortic graft infection with or without aortic valve involvement. Sixteen patients (41.0%) had genetically triggered thoracic aortic disease. Twelve patients (30.8%) had more than 1 prior sternotomy (mean, 2.4 ± 0.6). RESULTS: Valved homografts were used to replace the aortic root in 29 patients (74.4%); nonvalved homografts were used to replace the ascending aorta in 10 patients (25.6%). Twenty-five patients (64.1%) required concomitant proximal arch replacement with a homograft, and 2 patients (5.1%) required a total arch homograft. Median cardiopulmonary bypass, cardiac ischemia, and circulatory arrest times were 186 (137-253) minutes, 113 (59-151) minutes, and 28 (16-81) minutes. Operative mortality was 10.3% (n = 4). The rate of permanent stroke was 2.6% (n = 1); 3 additional patients had transient neurologic events. One patient (1/35, 2.9%) returned with aortic valve stenosis 10 years after the homograft operation. During the follow-up period (median, 2.5 years; range, 1 month to 12.3 years), no reinfection was reported, and survival was 65.7%. CONCLUSIONS: This is one of the largest North American single-center series of homograft use in reoperations on the proximal thoracic aorta to treat active endocarditis. In this high-risk population, homograft tissue can be used with acceptable early and midterm survival and a low risk of reinfection. When necessary, homograft tissue may be extended into the distal ascending and transverse aortic arch, with excellent results. These patients require long-term surveillance for both infection and implant durability.
OBJECTIVES: We examined the early and midterm outcomes of homograft use in reoperative aortic root and proximal aortic surgery for endocarditis and estimated the associated risk of postoperative reinfection. METHODS: From January 2001 to January 2014, 355 consecutive patients underwent reoperation of the proximal thoracic aorta. Thirty-nine patients (10.9%; mean age, 55.4 ± 13.3 years) presented with active endocarditis; 30 (76.9%) had prosthetic aortic root infection with or without concomitant ascending and arch graft infection, and 9 (23.1%) had proximal ascending aortic graft infection with or without aortic valve involvement. Sixteen patients (41.0%) had genetically triggered thoracic aortic disease. Twelve patients (30.8%) had more than 1 prior sternotomy (mean, 2.4 ± 0.6). RESULTS: Valved homografts were used to replace the aortic root in 29 patients (74.4%); nonvalved homografts were used to replace the ascending aorta in 10 patients (25.6%). Twenty-five patients (64.1%) required concomitant proximal arch replacement with a homograft, and 2 patients (5.1%) required a total arch homograft. Median cardiopulmonary bypass, cardiac ischemia, and circulatory arrest times were 186 (137-253) minutes, 113 (59-151) minutes, and 28 (16-81) minutes. Operative mortality was 10.3% (n = 4). The rate of permanent stroke was 2.6% (n = 1); 3 additional patients had transient neurologic events. One patient (1/35, 2.9%) returned with aortic valve stenosis 10 years after the homograft operation. During the follow-up period (median, 2.5 years; range, 1 month to 12.3 years), no reinfection was reported, and survival was 65.7%. CONCLUSIONS: This is one of the largest North American single-center series of homograft use in reoperations on the proximal thoracic aorta to treat active endocarditis. In this high-risk population, homograft tissue can be used with acceptable early and midterm survival and a low risk of reinfection. When necessary, homograft tissue may be extended into the distal ascending and transverse aortic arch, with excellent results. These patients require long-term surveillance for both infection and implant durability.
Authors: Davut Cekmecelioglu; Ourania Preventza; Kathryn G Dougherty; Subhasis Chatterjee; Susan Y Green; Guilherme V Silva; Jose G Díez; Joseph S Coselli Journal: Ann Cardiothorac Surg Date: 2021-09
Authors: Robert Novotny; Dasa Slizova; Jaroslav Hlubocky; Otakar Krs; Jaroslav Spatenka; Jan Burkert; Radovan Fiala; Petr Mitas; Pavel Mericka; Miroslav Spacek; Zuzana Hlubocka; Jaroslav Lindner Journal: PLoS One Date: 2017-04-17 Impact factor: 3.240
Authors: Alexander Horke; Igor Tudorache; Günther Laufer; Martin Andreas; Jose L Pomar; Daniel Pereda; Eduard Quintana; Marta Sitges; Bart Meyns; Filip Rega; Mark Hazekamp; Michael Hübler; Martin Schmiady; John Pepper; U Rosendahl; Artur Lichtenberg; Payam Akhyari; Ramadan Jashari; Dietmar Boethig; Dmitry Bobylev; Murat Avsar; Serghei Cebotari; Axel Haverich; Samir Sarikouch Journal: Eur J Cardiothorac Surg Date: 2020-11-01 Impact factor: 4.191
Authors: Giuseppe Nasso; Giuseppe Santarpino; Marco Moscarelli; Ignazio Condello; Angelo Maria Dell'Aquila; Armin Darius Peivandi; Mario Gaudino; Flavio Fiore; Pasquale Mastroroberto; Nicola Di Bari; Giuseppe Speziale Journal: Sci Rep Date: 2021-12-20 Impact factor: 4.379
Authors: Pietro Giorgio Malvindi; Elisa Mikus; Luca Caprili; Giuseppe Santarpino; Vito Margari; Simone Calvi; Giuseppe Nasso; Renato Gregorini; Carmine Carbone; Alberto Albertini; Giuseppe Speziale; Domenico Paparella Journal: Ann Cardiothorac Surg Date: 2019-11
Authors: Bo Yang; Juan Caceres; Linda Farhat; Tan Le; Bailey Brown; Emma St Pierre; Xiaoting Wu; Karen M Kim; Himanshu J Patel; G Michael Deeb Journal: J Thorac Cardiovasc Surg Date: 2020-04-13 Impact factor: 6.439
Authors: Marcin Szczechowicz; Alexander Weymann; Sabreen Mkalaluh; Ahmed Mashhour; Konstantin Zhigalov; Jerry Easo Journal: Braz J Cardiovasc Surg Date: 2020-06-01
Authors: Jerry Easo; Marcin Szczechowicz; Philipp Hölzl; Adrian Meyer; Konstantin Zhigalov; Rizwan Malik; Rohit Philip Thomas; Alexander Weymann; Otto E Dapunt Journal: Braz J Cardiovasc Surg Date: 2020-08-01